BioSpace News Archive

ImmunoGen’s FORWARD I trial was testing the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.

An analysis of the genetics of nearly 95,000 people across the United States and Europe who have been diagnosed with Alzheimer’s disease has led to the discovery of four new genetic variants in the body that can increase the risk of developing the form of dementia.

Most people would prefer to take a pill over an injection, and even an injection over an infusion. But not all drugs can be taken orally. In particular, this applies to most biologics, including insulin.

With concerns over the costs of prescription drugs taking center stage in American politics during a time when there are shortages of insulin and medical devices like EpiPens, it’s no wonder that the general public is frustrated and is calling on the government to take action of some kind.

Until recently, they were considered to be the three pillars of cancer treatment. Recent years have added a fourth pillar to surgery, radiation and chemotherapy—immuno-oncology.

CRISPR, the gene editing technique that promises to revolutionize healthcare and medicine, is not perfect. Two new studies, one in mice embryos and the other in rice plants, seem to confirm this.

Abpro, based in Woburn, Mass., inked a deal worth up to $4 billion with China-based Nanjing Chia Tai Tianqing Pharmaceutical Company, known as NJCTTQ, a global pharmaceutical company.

Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, announced that it has changed its name to Rakuten Medical, Inc.

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that the Company will be presenting mechanism of action findings and study design details at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium taking place February 28 to March 2 in San Francisco, CA.

Evofem Biosciences, Inc.,, a clinical stage biopharmaceutical company, reported financial results for the three- and twelve- month periods ended December 31, 2018.